Drugs / VA106483
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01330927 | Mar → Jul 2011 | benign prostatic hyperplasia | Vantia Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01171391 | Jul → Nov 2010 | — | Vantia Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00922740 | Jun → Jul 2009 | nocturnal enuresis | Vantia Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00879216 | Apr → May 2009 | nocturnal enuresis | Vantia Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00879138 | Aug 2008 → Feb 2009 | — | Vantia Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01038843 | Dec 2009 → Jul 2010 | nocturnal enuresis | Vantia Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VA106483 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00879216 ↗ |
| Action | Activate | “VA106483 is a selective vasopressin V2 receptor agonist” NCT00879138 ↗ |
| Modality | Small molecule | “VA106483 is a non-peptide drug” NCT01171391 ↗ |
| Route | Oral | “single and repeated oral doses of VA106483” NCT00879138 ↗ |